Biomea Fusion’s (BMEA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Biomea Fusion (NASDAQ:BMEA) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $16.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Biomea Fusion in a report on Tuesday, January 14th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $29.18.

Biomea Fusion Price Performance

Shares of BMEA opened at $2.87 on Wednesday. Biomea Fusion has a 1-year low of $2.35 and a 1-year high of $16.97. The stock has a market cap of $104.01 million, a PE ratio of -0.72 and a beta of -0.26. The firm has a 50-day simple moving average of $3.47 and a two-hundred day simple moving average of $6.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bayesian Capital Management LP acquired a new position in shares of Biomea Fusion during the fourth quarter worth $42,000. Wells Fargo & Company MN lifted its position in shares of Biomea Fusion by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock worth $50,000 after purchasing an additional 4,399 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Biomea Fusion during the fourth quarter worth $54,000. SG Americas Securities LLC bought a new stake in shares of Biomea Fusion in the fourth quarter worth $58,000. Finally, Maia Wealth LLC bought a new stake in shares of Biomea Fusion in the fourth quarter worth $62,000. 96.72% of the stock is owned by institutional investors and hedge funds.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.